API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Lovenox (enoxaparin sodium) is a novel small molecule Antithrombin-III activator. It is an anticoagulant medicine indicated for the treatment of venous thromboembolism including deep vein thrombosis.
Lead Product(s): Enoxaparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lovenox
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
The agreement aims for the for the localization of the full range of its flagship market leader product, Clexane (enoxaparin sodium), used to prevent clots from getting bigger or stopping new clots from forming.
Lead Product(s): Enoxaparin Sodium
Therapeutic Area: Hematology Product Name: Clexane
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 10, 2023
Details:
Lovenox-Generic (enoxaparin sodium) is a Factor XI/XIa inhibitor with a Prefilled Syringes with 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths low molecular weight heparin (LMWH), is an anticoagulant that helps to prevent thrombosis.
Lead Product(s): Enoxaparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lovenox-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
Enoxaparin sodium binds to antithrombin III, a serine protease inhibitor, forming a complex that irreversibly inactivates factor Xa, which is frequently used to monitor anticoagulation in the clinical setting.
Lead Product(s): Enoxaparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lovenox-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
Researchers found that patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, lower cost, and better clinical outcomes in Covid-19 patient.
Lead Product(s): Enoxaparin Sodium
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Premier
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
Redesca™ is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism.
Lead Product(s): Enoxaparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Redesca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
Meitheal Pharmaceuticals has launched Enoxaparin Sodium Injection, generic equivalent of Lovenox®, in the United States market. Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Lead Product(s): Enoxaparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020